CLINICAL_TRIALS ClinicalTrials.gov record update

Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.]

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00423046
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:27.560633+00:00
Published At: 2010-08-25T00:00:00+00:00
Record Updated At: 2020-01-02
Results Posted At: 2010-08-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Infections, Papillomavirus", "Papillomavirus Vaccines"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-01-02"
protocolSection.identificationModule.nctId: "NCT00423046"
protocolSection.identificationModule.officialTitle: "Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals\u0027 HPV-16/18 L1/AS04 Vaccine Versus Gardasil\u00ae [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck \u0026 Co., Inc.]"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2010-08-25"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.